COMMUNIQUÉS West-GlobeNewswire

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

08/11/2024 - 15:55

The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval The award to CervoMed recognizes the [...]

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

08/11/2024 - 16:00

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2 SK ) to the tumor microenvironment (TME), where [...]

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

08/11/2024 - 16:05

New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy. Predictive biomarkers correlated [...]

BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences

08/11/2024 - 17:03

8 November 2024 New Release BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of T he NGAL Test to Clinicians at Major Healthcare Conferences COPENHAGEN, DENMARK and BOSTON [...]

GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Gene Vector Therapy, at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

08/11/2024 - 12:00

GEN2 was studied in patients with hepatocellular carcinoma or advanced solid tumors metastatic to the liver and was well-tolerated at all dose levels administered 21% of patients remained on study for >6 months, with [...]

AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina

08/11/2024 - 12:00

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and potentially transformative therapy for patients with neovascular and [...]

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

08/11/2024 - 12:09

Consolidated net revenue of € 1,743.1 million in the first nine months, +12.0% or +9.3% on a like-for-like basis (3) and at constant exchange rates (CER) EBITDA (1) of € 665.7 million, +11.8%, revenue margin of 38.2% [...]

Fortrea Reports Third Quarter 2024 Results

08/11/2024 - 12:30

For the three months ended September 30, 2024, from continuing operations: Revenues of $674.9 million GAAP net loss of $(18.5) million Adjusted EBITDA of $64.2 million GAAP and adjusted net income (loss) per diluted [...]

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

08/11/2024 - 12:35

Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024 Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment [...]

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

08/11/2024 - 12:45

Conference Call and Webcast Today at 8:30 a.m. ET Subsequent to quarter-end, closed $30 million in debt financing OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to complete enrollment in [...]

ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance

08/11/2024 - 12:50

Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5% , and record Purified Cortrophin® Gel net revenues of $52.6 million, an increase of 76.8% year-over-year Net loss of [...]

Apyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook

08/11/2024 - 13:00

Strengthened balance sheet with a common stock registered direct offering with gross proceeds of approximately $7.0 million; and amended revenue covenants for the Company’s credit agreement with Perceptive Announces [...]

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

08/11/2024 - 13:00

– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for [...]

Bright Peak Therapeutics Presents New Data at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

08/11/2024 - 13:00

-- BPT958, a bifunctional PD-1 immunoconjugate with a masked IL-2 payload designed to be processed specifically in the tumor microenvironment - --In preclinical models, BPT958 induces potent antitumor activity with [...]

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

08/11/2024 - 13:00

— First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH — — Phase 3 SYNCHRONY Real-World and Histology studies on track to [...]

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

08/11/2024 - 13:00

NEW HAVEN, Conn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today [...]

Immunocore to present at upcoming investor conferences

08/11/2024 - 13:00

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering [...]

Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024

08/11/2024 - 13:00

HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted [...]

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO®/DARZALEX® (daratumumab) as subcutaneous monotherapy for high-risk smouldering multiple myeloma

08/11/2024 - 13:00

If approved, daratumumab will become the first treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before the onset of active [...]